The Dose
News Desk
The Dose is the daily news publication of GLP1 Clinics, delivering timely coverage of the GLP-1 medication landscape. From FDA approvals and clinical trial results to insurance policy changes and drug pricing updates, The Dose keeps patients and providers informed about developments that affect access to weight loss treatment.
Areas of Expertise
Articles by The Dose
CMS Extends Medicare GLP-1 Bridge Through 2027 as Main Program Stalls
Medicare's temporary GLP-1 coverage program gets 18-month extension while the permanent BALANCE model faces uncertainty over insurer participation.
FDA Proposes to Block Large-Scale GLP-1 Compounding in Major Access Shift
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from its 503B bulks list, potentially ending large-scale compounding of affordable GLP-1 alternatives for good.
FDA Opens First Public Review of Revolutionary Fast-Track Drug Program
The FDA will hold its first public meeting on June 4 to review the Commissioner's National Priority Voucher program that has cut drug approval times from 10-12 months to just 1-2 months.
FDA Sets New 'Four Prescription' Limit for Compounded GLP-1 Drugs
New FDA guidance restricts compounding pharmacies to just four monthly prescriptions of compounded GLP-1 copies, tightening access to affordable alternatives.
Lilly's Foundayo Sees Modest Launch with Just 1,390 Prescriptions in Debut Week
Eli Lilly's new oral GLP-1 pill Foundayo recorded only 1,390 prescriptions in its first week, a surprisingly modest start that contrasts sharply with Novo's oral Wegovy success.
Why 1 in 10 People May Be Genetically Resistant to GLP-1 Drugs Like Ozempic
New Stanford research reveals specific genetic variants in 10% of people cause 'GLP-1 resistance,' explaining why Ozempic and Wegovy work poorly for some users despite having higher hormone levels.
Landmark Study Reveals GLP-1 Drugs' Surprising Health Benefits Beyond Weight Loss
A massive new analysis of 123 studies finds GLP-1 medications reduce risks for heart disease, kidney problems, cognitive decline, and fractures—reshaping how doctors think about these drugs.
Semaglutide Patent Expires in India, Triggering Generic GLP-1 Price War
Novo Nordisk's semaglutide patent expired in India on March 20, unleashing a wave of generic versions that cost 77% less than branded Ozempic and reshaping global GLP-1 access.
Medicare Launches Historic GLP-1 Coverage Bridge in July 2026
Medicare's new GLP-1 Bridge starts July 2026, offering Wegovy and Zepbound for $50/month to eligible beneficiaries with obesity and comorbidities.
Medicare Expands GLP-1 Coverage to 3.4 Million Seniors Under New CMS Rule
New Medicare rule reinterprets GLP-1 coverage criteria, enabling 3.4 million beneficiaries to access weight loss medications through cardiovascular risk reduction pathway.
Lilly's Retatrutide Delivers Record 28.7% Weight Loss in First Phase 3 Trial
Eli Lilly's triple-agonist retatrutide achieved 28.7% average weight loss (71.2 pounds) in its first successful Phase 3 trial, setting a new efficacy record for obesity medications.
Eli Lilly's Triple Agonist Retatrutide Achieves 2% A1C Drop in Phase 3
Lilly's experimental retatrutide delivered up to 2% A1C reduction and 16.8% weight loss in its first Phase 3 diabetes trial, positioning it as a potential challenger to current GLP-1 therapies.
FDA Issues 30 Warning Letters in Major GLP-1 Compounding Crackdown
The FDA sent warning letters to 30 telehealth companies on March 3, marking the largest enforcement action against compounded GLP-1 marketing in the agency's history.
Walgreens Disrupts GLP-1 Market with Subscription-Free Weight Management
Major retail pharmacy launches $49 pay-per-visit GLP-1 program in 28 states, challenging telehealth subscription model with no monthly fees required.
Major Medical Groups Release First Joint Nutrition Guidelines for GLP-1s
Four leading medical organizations publish comprehensive nutritional guidelines for GLP-1 therapy, emphasizing the importance of personalized nutrition and lifestyle support.
FDA Approves Higher-Dose Wegovy Under New Fast-Track Review Program
The FDA approved Wegovy HD (7.2 mg) under its new National Priority Voucher program, delivering 20.7% average weight loss and cutting review times to just 2 months.